Predicting active disease (DAS>2.4) at 3 months with (prognostic) variable(s), using univariate logistic regression (A) and logistic regression model with backward selection (B)
| OR (95% CI) | p Value | |
|---|---|---|
| A. | ||
| Age (years) | 1.01 (0.98 to 1.03) | 0.72 |
| Sex (1=female) | 4.07 (1.61 to 10.27) | 0.003 |
| Symptom duration (days) | 1.00 (0.99 to 1.00) | 0.387 |
| RF (1=positive) | 0.59 (0.27 to 1.29) | 0.187 |
| ACPA (1=positive) | 0.66 (0.30 to 1.48) | 0.318 |
| Erosion typical for RA (1=present) | 0.41 (0.13 to 1.31) | 0.132 |
| GCs response at 2 weeks (ref.=good) | ||
| Moderate | 4.09 (1.43 to 11.72) | 0.009 |
| None | 10.29 (3.34 to 31.64) | <0.001 |
| Treatment (ref.=MTX+GCs oral) | ||
| MTX+SSZ+HCQ+GCs IM | 0.28 (0.11 to 0.71) | 0.007 |
| MTX+SSZ+HCQ+GCs oral | 0.28 (0.11 to 0.73) | 0.009 |
| DAS | 3.50 (1.95 to 6.30) | <0.001 |
| TJC44 | 1.13 (1.06 to 1.19) | <0.001 |
| ESR (mm/h) | 1.01 (1.00 to 1.04) | 0.062 |
| General health (0–100 mm) | 1.02 (1.00 to 1.04) | 0.017 |
| B. | ||
| Sex (1=female) | 5.98 (1.67 to 21.40) | 0.006 |
| GCs response at 2 weeks (ref.=good) | ||
| Moderate | 1.67 (0.48 to 5.88) | 0.424 |
| None | 14.00 (3.31 to 59.21) | <0.001 |
| Treatment (ref.=MTX+GCs oral) | ||
| MTX+SSZ+HCQ+GCs IM | 0.25 (0.07 to 0.90) | 0.03 |
| MTX+SSZ+HCQ+GCs oral | 0.18 (0.05 to 0.69) | 0.01 |
| DAS | 5.54 (2.55 to 12.04) | <0.001 |
ACPA, anti-citrullinated peptide antibodies; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SSZ, sulfasalazine; TJC44, tender joint count (44 joints).